Lorraine Soisson

United States Agency for International Development — United States

Medicine · Health Sciences

27h-index3.0kcitations52works10.32yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Malaria Research and Control(38), Mosquito-borne diseases and control(31), vaccines and immunoinformatics approaches(15), HIV Research and Treatment(11), Computational Drug Discovery Methods(6)

Publications52 total

Comparison of major, minor and junctional circumsporozoite protein epitopes for malaria vaccine design
npj Vaccines·2025Open Access
Human responses to the DNA prime/chimpanzee adenovirus (ChAd63) boost vaccine identify CSP, AMA1 and TRAP MHC Class I-restricted epitopes
PLoS ONE·2025· 1 citedOpen Access
Analysis of the diverse antigenic landscape of the malaria protein RH5 identifies a potent vaccine-induced human public antibody clonotype
Cell·2024· 24 citedOpen Access
Preclinical development of a stabilized RH5 virus-like particle vaccine that induces improved antimalarial antibodies
Cell Reports Medicine·2024· 19 citedOpen Access
Development of an improved blood-stage malaria vaccine targeting the essential RH5-CyRPA-RIPR invasion complex
Nature Communications·2024· 27 citedOpen Access
A phase IIa, randomized, double-blind, safety, immunogenicity and efficacy trial of Plasmodium falciparum vaccine antigens merozoite surface protein 1 and RTS,S formulated with AS02 adjuvant in healthy, malaria-naïve adults
Vaccine·2024· 3 citedOpen Access
Development of an improved blood-stage malaria vaccine targeting the essential RH5-CyRPA-RIPR invasion complex
2024· 1 citedOpen Access
Preclinical Development of a Stabilized RH5 Virus-Like Particle Vaccine that Induces Improved Anti-Malarial Antibodies
2024· 7 citedOpen Access
Analysis of the Diverse Antigenic Landscape of the Malaria Invasion Protein RH5 Identifies a Potent Vaccine-Induced Human Public Antibody Clonotype
2023· 10 citedOpen Access
RH5.1-CyRPA-Ripr antigen combination vaccine shows little improvement over RH5.1 in a preclinical setting
Frontiers in Cellular and Infection Microbiology·2022· 20 citedOpen Access
The Importance of Exercising Caution When Comparing Results from Malaria Vaccines Administered on the EPI Schedule and on a Seasonal Schedule
American Journal of Tropical Medicine and Hygiene·2022· 9 citedOpen Access
First-in-human assessment of safety and immunogenicity of low and high doses of Plasmodium falciparum malaria protein 013 (FMP013) administered intramuscularly with ALFQ adjuvant in healthy malaria-naïve adults
Vaccine·2022· 25 citedOpen Access
Restricted valency (NPNA)n repeats and junctional epitope-based circumsporozoite protein vaccines against Plasmodium falciparum
npj Vaccines·2022· 20 citedOpen Access
A three-antigen Plasmodium falciparum DNA prime—Adenovirus boost malaria vaccine regimen is superior to a two-antigen regimen and protects against controlled human malaria infection in healthy malaria-naïve adults
PLoS ONE·2021· 21 citedOpen Access
Reduced blood-stage malaria growth and immune correlates in humans following RH5 vaccination
Med·2021· 156 citedOpen Access
Immunoglobulin G subclass and antibody avidity responses in Malian children immunized with Plasmodium falciparum apical membrane antigen 1 vaccine candidate FMP2.1/AS02A
Malaria Journal·2019· 11 citedOpen Access
MOESM2 of Immunoglobulin G subclass and antibody avidity responses in Malian children immunized with Plasmodium falciparum apical membrane antigen 1 vaccine candidate FMP2.1/AS02A
Figshare·2019Open Access
MOESM3 of Immunoglobulin G subclass and antibody avidity responses in Malian children immunized with Plasmodium falciparum apical membrane antigen 1 vaccine candidate FMP2.1/AS02A
Figshare·2019Open Access
MOESM1 of Immunoglobulin G subclass and antibody avidity responses in Malian children immunized with Plasmodium falciparum apical membrane antigen 1 vaccine candidate FMP2.1/AS02A
Figshare·2019Open Access
EFFICACY OF THE NOVEL PLASMODIUM FALCIPARUM BLOOD-STAGE VACCINE RH5.1/AS01B IN A PHASE I/IIA CLINICAL TRIAL
Oxford University Research Archive (ORA) (University of Oxford)·2018Open Access
page 1 of 3Next →

Frequent Co-authors

Carter L. Diggs(31), Sheetij Dutta(22), D. Gray Heppner(16), Evelina Angov(12), Carole A. Long(12), Mahamadou A. Théra(11), Ogobara K. Doumbo(11), Drissa Coulibaly(11), David E. Lanar(11), Christopher V. Plowe(11), Sarah E. Silk(11), Kazutoyo Miura(11), Simon J. Draper(11), Martha Sedegah(11), Harini Ganeshan(11), Michael R. Hollingdale(11), Amadou Niangaly(10), María Belmonte(10), Keith Limbach(10), Matthew B. Laurens(9)